Patents by Inventor Samir Kulkarni
Samir Kulkarni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11926642Abstract: The invention relates to compounds of formula I wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.Type: GrantFiled: July 1, 2021Date of Patent: March 12, 2024Assignee: Pfizer inc.Inventors: Robert Steven Kania, Padmavani Bezawada, Emma Louise Hawking, Rohit Jaini, Samir Kulkarni, Matthew Nathan O'Brien Laramy, Jonathan Richard Lillis, Suman Luthra, Dafydd Rhys Owen, Klimentina Dimitrova Pencheva, Anil Mahadeo Rane, Matthew Forrest Sammons, Bradley Paul Sullivan, Andrew John Thiel, Martyn David Ticehurst, Jamison Bryce Tuttle, Robert Louis Hoffman
-
Patent number: 11897908Abstract: Solid forms of L-glufosinate materials, including crystalline L-glufosinate ammonium, are described.Type: GrantFiled: March 8, 2023Date of Patent: February 13, 2024Assignee: BASF SEInventors: Stephen Craig Fields, Matthew Richard Oberholzer, Brian Michael Green, Samir Kulkarni, Jennifer Nelson, Patricia Andres
-
Patent number: 11897909Abstract: Solid forms of L-glufosinate materials, including crystalline L-glufosinate ammonium, are described.Type: GrantFiled: March 8, 2023Date of Patent: February 13, 2024Assignee: BASF SEInventors: Stephen Craig Fields, Matthew Richard Oberholzer, Brian Michael Green, Samir Kulkarni, Jennifer Nelson, Patricia Andres
-
Publication number: 20230331749Abstract: Compositions and methods for isolating L-glufosinate from a composition comprising L-glufosinate and glutamate are provided. The method comprises converting the glutamate to pyroglutamate followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The composition comprising L-glufosinate and glutamate is subjected to an elevated temperature for a sufficient time to allow for the conversion of glutamate to pyroglutamate, followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The glutamate alternatively may be converted to pyroglutamate by enzymatic conversion. The purified L-glufosinate is present in a final composition at a concentration of 90% or greater of the sum of L-glufosinate, glutamate, and pyroglutamate.Type: ApplicationFiled: March 8, 2023Publication date: October 19, 2023Inventors: Stephen Craig Fields, Matthew Richard Oberholzer, Brian Michael Green, Samir Kulkarni, Jennifer Nelson, Patricia Andres
-
Publication number: 20230219985Abstract: Compositions and methods for isolating L-glufosinate from a composition comprising L-glufosinate and glutamate are provided. The method comprises converting the glutamate to pyroglutamate followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The composition comprising L-glufosinate and glutamate is subjected to an elevated temperature for a sufficient time to allow for the conversion of glutamate to pyroglutamate, followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The glutamate alternatively may be converted to pyroglutamate by enzymatic conversion. The purified L-glufosinate is present in a final composition at a concentration of 90% or greater of the sum of L-glufosinate, glutamate, and pyroglutamate.Type: ApplicationFiled: March 8, 2023Publication date: July 13, 2023Inventors: Stephen Craig Fields, Matthew Richard Oberholzer, Brian Michael Green, Samir Kulkarni, Jennifer Nelson, Patricia Andres
-
Publication number: 20230219984Abstract: Compositions and methods for isolating L-glufosinate from a composition comprising L-glufosinate and glutamate are provided. The method comprises converting the glutamate to pyroglutamate followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The composition comprising L-glufosinate and glutamate is subjected to an elevated temperature for a sufficient time to allow for the conversion of glutamate to pyroglutamate, followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The glutamate alternatively may be converted to pyroglutamate by enzymatic conversion. The purified L-glufosinate is present in a final composition at a concentration of 90% or greater of the sum of L-glufosinate, glutamate, and pyroglutamate.Type: ApplicationFiled: March 8, 2023Publication date: July 13, 2023Inventors: Stephen Craig Fields, Matthew Richard Oberholzer, Brian Michael Green, Samir Kulkarni, Jennifer Nelson, Patricia Andres
-
Patent number: 11634442Abstract: Compositions and methods for isolating L-glufosinate from a composition comprising L-glufosinate and glutamate are provided. The method comprises converting the glutamate to pyroglutamate followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The composition comprising L-glufosinate and glutamate is subjected to an elevated temperature for a sufficient time to allow for the conversion of glutamate to pyroglutamate, followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The glutamate alternatively may be converted to pyroglutamate by enzymatic conversion. The purified L-glufosinate is present in a final composition at a concentration of 90% or greater of the sum of L-glufosinate, glutamate, and pyroglutamate.Type: GrantFiled: July 17, 2018Date of Patent: April 25, 2023Assignee: BASF SEInventors: Stephen Craig Fields, Matthew Richard Oberholzer, Brian Michael Green, Samir Kulkarni, Jennifer Nelson, Patricia Andres
-
Publication number: 20220017548Abstract: The invention relates to compounds of formula I wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.Type: ApplicationFiled: July 1, 2021Publication date: January 20, 2022Applicant: Pfizer Inc.Inventors: Robert Steven Kania, Padmavani Bezawada, Emma Louise Hawking, Rohit Jaini, Samir Kulkarni, Matthew Nathan O'Brien Laramy, Jonathan Richard Lillis, Suman Luthra, Dafydd Rhys Owen, Klimentina Dimitrova Pencheva, Martin Youngjin Pettersson, Anil Mahadeo Rane, Matthew Forrest Sammons, Bradley Paul Sullivan, Andrew John Thiel, Martyn David Ticehurst, Jamison Bryce Tuttle, Robert Louis Hoffman
-
Patent number: 10828578Abstract: Aspects of the disclosure relate to methods and compositions of altering a solution through the use of readily retrievable agents (e.g., a nanoparticle) having one or more functional groups configured to undergo a solvation interaction with a component of the solution. Compositions, systems, and methods for crystallizing organic and inorganic compounds from solutions using nanoparticles surface coated with functional groups that create a supersaturated state in the solution and reversal thereof. Compositions, systems, and methods for purifying water or active pharmaceutical ingredients. Compositions, systems, and methods for increasing the solubility of a solution and reversal of the same. Compositions, systems, and methods for decreasing the solubility of a crystallized compound and reversal of the same.Type: GrantFiled: April 6, 2017Date of Patent: November 10, 2020Assignee: Massachusetts Institute of TechnologyInventors: Allan S. Myerson, Samir Kulkarni
-
Publication number: 20200181179Abstract: Compositions and methods for isolating L-glufosinate from a composition comprising L-glufosinate and glutamate are provided. The method comprises converting the glutamate to pyroglutamate followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The composition comprising L-glufosinate and glutamate is subjected to an elevated temperature for a sufficient time to allow for the conversion of glutamate to pyroglutamate, followed by the isolation of L-glufosinate from the pyroglutamate and other components of the composition to obtain substantially purified L-glufosinate. The glutamate alternatively may be converted to pyroglutamate by enzymatic conversion. The purified L-glufosinate is present in a final composition at a concentration of 90% or greater of the sum of L-glufosinate, glutamate, and pyroglutamate.Type: ApplicationFiled: July 17, 2018Publication date: June 11, 2020Applicant: AGRIMETIS, LLCInventors: Stephen Craig Fields, Matthew Richard Oberholzer, Brian Michael Green, Samir Kulkarni, Jennifer Nelson, Patricia Andres
-
Publication number: 20190160392Abstract: Aspects of the disclosure relate to methods and compositions of altering a solution through the use of readily retrievable agents (e.g., a nanoparticle) having one or more functional groups configured to undergo a solvation interaction with a component of the solution. Compositions, systems, and methods for crystallizing organic and inorganic compounds from solutions using nanoparticles surface coated with functional groups that create a supersaturated state in the solution and reversal thereof. Compositions, systems, and methods for purifying water or active pharmaceutical ingredients. Compositions, systems, and methods for increasing the solubility of a solution and reversal of the same. Compositions, systems, and methods for decreasing the solubility of a crystallized compound and reversal of the same.Type: ApplicationFiled: April 6, 2017Publication date: May 30, 2019Applicant: Massachusetts Institute of TechnologyInventors: Allan S. Myerson, Samir Kulkarni
-
Publication number: 20140128577Abstract: Provided is a method for purification of TNFR:Fc fusion protein comprising hydrophobic interaction chromatography, wherein the buffer solution used in the said chromatography does not contain any additives.Type: ApplicationFiled: June 22, 2012Publication date: May 8, 2014Applicant: DR. REDDY'S LABORATORIES LIMITEDInventors: Samir Kulkarni, Ravikant Devakate, Neeru Gupta, Prashant Kardekar
-
Publication number: 20130178608Abstract: The application describes an antibody purification method comprising multiple chromatographic steps wherein the low pH eluate from a protein A chromatography is further purified without the need of substantial pH adjustment.Type: ApplicationFiled: December 28, 2010Publication date: July 11, 2013Inventors: Samir Kulkarni, Satyam Subrahmanyam
-
Publication number: 20130116413Abstract: The invention describes a method for protein purification. More particularly, the invention relates to a purification process comprising protein A chromatography and anion exchange chromatography wherein protein A chromatography eluate is further purified by anion exchange chromatography at similar pH or at a pH less than or equal to 6.Type: ApplicationFiled: December 28, 2010Publication date: May 9, 2013Applicants: DR. REDDY'S LABORATORIES, INC., DR. REDDY'S LABORATORIES LTD.Inventors: Samir Kulkarni, Satyam Subrahmanyam, Y. Raghvendra, Prashant Kardekar
-
Publication number: 20110288045Abstract: The present invention describes a method and composition for a pharmaceutical product based on Tenofovir disoproxil hemifumarate, Emtricitabine and Efavirenz. The composition can be prepared by a process comprising a wet granulation step to produce a stable dosage form suitable for the treatment of HIV in essential absence of known degradation products.Type: ApplicationFiled: November 19, 2009Publication date: November 24, 2011Applicant: ULTIMORPHIX TECHNOLOGIES B.V.Inventors: Rita Ramos, Evanthia Dova, Samir Kulkarni, Marcel Hoffmann